Hovione Acquires a Formulation Plant
Hovione is investing in specialized formulation capabilities. The first step of the plan was the acquisition of a formulation facility adjacent to the company’s current process chemistry and particle engineering facility in Loures, Portugal. This acquisition is a strategic investment to further boost development and manufacturing capabilities for both inhalation and oral dosage forms.
The facility will be engineered to enable to work with highly potent active pharmaceutical ingredients and moisture-sensitive compounds and will have dedicated rooms to allow for concurrent manufacture of these products. The facility will be capable to prepare a wide range of materials suitable for clinical trials as well as commercial batches meeting global regulatory requirements. The company has four FDA inspected sites in the US, China, Ireland, and Portugal.